Staff Members - Benha University
Effect of tumor necrosis factor alpha inhibition with etanercept on renal functions in L-NAME induced hypertensive rats: insights into the possible mechanisms
• 2022
Publication Information
Authors
Mona A. Said, Reham M. Ibrahim & Mona M. Allam
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Many studies suggest the dominant role of the inflammatory cytokine,
tumor necrosis factor alpha (TNF-α) in the prognosis of hypertension and end
stage renal disease (ESRD). The objective of this study was to investigate the
effects of TNF-α inhibition on renal functions in Nω
-nitro-L-arginine methyl ester
(L-NAME) induced hypertensive rats and the potential underlying mechanisms.
Four groups of rats were used in the study for 3 weeks period; normal control
group, TNF- α inhibitor (etanercept) group, L-NAME-induced hypertensive
group and L-NAME + etanercept group. L-NAME group showed elevated
systolic and diastolic blood pressure, plasma urea, creatinine, plasma renin
activity, angiotensin II, kidney tissue nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase, TNF- α and malondialdehyde (MDA) together
with decreased creatinine clearance rate and renal antioxidants. Treatment with
etanercept affords antihypertensive effect and ameliorates L-NAME induced
renal impairment by improving renin–angiotensin system (RAS) and NADPH
oxidase as well as by attenuating oxidative stress.
tumor necrosis factor alpha (TNF-α) in the prognosis of hypertension and end
stage renal disease (ESRD). The objective of this study was to investigate the
effects of TNF-α inhibition on renal functions in Nω
-nitro-L-arginine methyl ester
(L-NAME) induced hypertensive rats and the potential underlying mechanisms.
Four groups of rats were used in the study for 3 weeks period; normal control
group, TNF- α inhibitor (etanercept) group, L-NAME-induced hypertensive
group and L-NAME + etanercept group. L-NAME group showed elevated
systolic and diastolic blood pressure, plasma urea, creatinine, plasma renin
activity, angiotensin II, kidney tissue nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase, TNF- α and malondialdehyde (MDA) together
with decreased creatinine clearance rate and renal antioxidants. Treatment with
etanercept affords antihypertensive effect and ameliorates L-NAME induced
renal impairment by improving renin–angiotensin system (RAS) and NADPH
oxidase as well as by attenuating oxidative stress.